Nature Reviews Cancer：抗癌药物直达肿瘤新技术

2015-05-28 佚名生物谷

肿瘤在生物体内复杂的微环境结构影响到药物的扩散和分布，也让药物敏感性和肿瘤应答的研究较为困难。为了解决这个问题，研究者们最近开发出两种不同的新技术，可以将多种抗癌药物直接运送至肿瘤部位，研究药物分布和细胞毒性。最新一期的《Nature Review Cancer》杂志对此进行了介绍。麻省理工(MIT)的Jonas等人研制出的小型圆柱载体包含了16个储藏小室。该载体可以用标准活检针直接植入老

肿瘤在生物体内复杂的微环境结构影响到药物的扩散和分布，也让药物敏感性和肿瘤应答的研究较为困难。为了解决这个问题，研究者们最近开发出两种不同的新技术，可以将多种抗癌药物直接运送至肿瘤部位，研究药物分布和细胞毒性。最新一期的《Nature Review Cancer》杂志对此进行了介绍。

麻省理工(MIT)的Jonas等人研制出的小型圆柱载体包含了16个储藏小室。该载体可以用标准活检针直接植入老鼠体内的肿瘤部位，并停留24个小时。储藏小室之间相互分开，可以用来装入不同的药物。药物通过被动运输迅速释放至周围的肿瘤组织，之后再用更大的针移除该装置及其周围组织，进而检测癌细胞对药物的反应。研究者们已经用此装置检测了阿霉素在内的多种药物在异种移植的人乳腺癌模型里的分布，给药浓度和肿瘤应答。

与此同时，来自西雅图Presage Biosciences的研究人员Klinghoffer等人创新发明的CIVO微注射技术，可以通过皮肤注射多达八种不同药物到肿瘤内。CIVO装置包含数个微型针头，每一个针头包含一种药物以及惰性示踪染料。在原位注射药物之后，肿瘤组织被切下，该产品自带的自动分析装置将检测药物在癌细胞内的作用。目前，CIVO在四名病人体内的初步实验显示其具有良好的安全性，更大规模的临床实验即将展开。

这两种新技术在未来拥有着广泛用途，包括药物的细胞穿透性和稳定性评估，药物的筛选，以及临床实验中药物最适浓度的选择等。

原始出处:

M. Teresa Villanueva.Get in there!Nature Reviews Cancer, May 22, 2015.doi:10.1038/nrc3963

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (12)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1880677, encodeId=b50618806e750, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 13 03:12:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59867, encodeId=40875986ec9, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:01:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59868, encodeId=a2275986832, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:01:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741264, encodeId=2e591e41264a2, content=<a href='/topic/show?id=329f1540333' target=_blank style='color:#2F92EE;'>#reviews#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15403, encryptionId=329f1540333, topicName=reviews)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9be134907862, createdName=12498ebem30暂无昵称, createdTime=Sat Jul 25 16:12:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995808, encodeId=6f2819958081d, content=<a href='/topic/show?id=a1751540260' target=_blank style='color:#2F92EE;'>#review#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15402, encryptionId=a1751540260, topicName=review)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Thu Apr 14 04:12:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903694, encodeId=098f1903694ae, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon May 02 08:12:00 CST 2016, time=2016-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25586, encodeId=6a612558628, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:18:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308211, encodeId=744b1308211cf, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sat May 30 00:12:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314631, encodeId=104813146318c, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat May 30 00:12:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25202, encodeId=958a252020f, content=科技先进啊！, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Thu May 28 16:20:00 CST 2015, time=2015-05-28, status=1, ipAttribution=)]
2016-04-13 liye789132251

#Nat#

30 0
[GetPortalCommentsPageByObjectIdResponse(id=1880677, encodeId=b50618806e750, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 13 03:12:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59867, encodeId=40875986ec9, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:01:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59868, encodeId=a2275986832, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:01:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741264, encodeId=2e591e41264a2, content=<a href='/topic/show?id=329f1540333' target=_blank style='color:#2F92EE;'>#reviews#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15403, encryptionId=329f1540333, topicName=reviews)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9be134907862, createdName=12498ebem30暂无昵称, createdTime=Sat Jul 25 16:12:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995808, encodeId=6f2819958081d, content=<a href='/topic/show?id=a1751540260' target=_blank style='color:#2F92EE;'>#review#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15402, encryptionId=a1751540260, topicName=review)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Thu Apr 14 04:12:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903694, encodeId=098f1903694ae, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon May 02 08:12:00 CST 2016, time=2016-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25586, encodeId=6a612558628, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:18:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308211, encodeId=744b1308211cf, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sat May 30 00:12:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314631, encodeId=104813146318c, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat May 30 00:12:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25202, encodeId=958a252020f, content=科技先进啊！, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Thu May 28 16:20:00 CST 2015, time=2015-05-28, status=1, ipAttribution=)]
2016-01-26 doctording1

这篇文章有一定深度

116 0
[GetPortalCommentsPageByObjectIdResponse(id=1880677, encodeId=b50618806e750, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 13 03:12:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59867, encodeId=40875986ec9, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:01:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59868, encodeId=a2275986832, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:01:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741264, encodeId=2e591e41264a2, content=<a href='/topic/show?id=329f1540333' target=_blank style='color:#2F92EE;'>#reviews#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15403, encryptionId=329f1540333, topicName=reviews)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9be134907862, createdName=12498ebem30暂无昵称, createdTime=Sat Jul 25 16:12:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995808, encodeId=6f2819958081d, content=<a href='/topic/show?id=a1751540260' target=_blank style='color:#2F92EE;'>#review#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15402, encryptionId=a1751540260, topicName=review)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Thu Apr 14 04:12:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903694, encodeId=098f1903694ae, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon May 02 08:12:00 CST 2016, time=2016-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25586, encodeId=6a612558628, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:18:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308211, encodeId=744b1308211cf, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sat May 30 00:12:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314631, encodeId=104813146318c, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat May 30 00:12:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25202, encodeId=958a252020f, content=科技先进啊！, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Thu May 28 16:20:00 CST 2015, time=2015-05-28, status=1, ipAttribution=)]
2016-01-26 doctording1

是一篇不错的文章

146 0
[GetPortalCommentsPageByObjectIdResponse(id=1880677, encodeId=b50618806e750, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 13 03:12:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59867, encodeId=40875986ec9, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:01:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59868, encodeId=a2275986832, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:01:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741264, encodeId=2e591e41264a2, content=<a href='/topic/show?id=329f1540333' target=_blank style='color:#2F92EE;'>#reviews#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15403, encryptionId=329f1540333, topicName=reviews)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9be134907862, createdName=12498ebem30暂无昵称, createdTime=Sat Jul 25 16:12:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995808, encodeId=6f2819958081d, content=<a href='/topic/show?id=a1751540260' target=_blank style='color:#2F92EE;'>#review#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15402, encryptionId=a1751540260, topicName=review)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Thu Apr 14 04:12:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903694, encodeId=098f1903694ae, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon May 02 08:12:00 CST 2016, time=2016-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25586, encodeId=6a612558628, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:18:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308211, encodeId=744b1308211cf, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sat May 30 00:12:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314631, encodeId=104813146318c, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat May 30 00:12:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25202, encodeId=958a252020f, content=科技先进啊！, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Thu May 28 16:20:00 CST 2015, time=2015-05-28, status=1, ipAttribution=)]
2015-07-25 12498ebem30暂无昵称

#reviews#

34 0
[GetPortalCommentsPageByObjectIdResponse(id=1880677, encodeId=b50618806e750, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 13 03:12:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59867, encodeId=40875986ec9, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:01:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59868, encodeId=a2275986832, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:01:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741264, encodeId=2e591e41264a2, content=<a href='/topic/show?id=329f1540333' target=_blank style='color:#2F92EE;'>#reviews#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15403, encryptionId=329f1540333, topicName=reviews)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9be134907862, createdName=12498ebem30暂无昵称, createdTime=Sat Jul 25 16:12:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995808, encodeId=6f2819958081d, content=<a href='/topic/show?id=a1751540260' target=_blank style='color:#2F92EE;'>#review#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15402, encryptionId=a1751540260, topicName=review)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Thu Apr 14 04:12:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903694, encodeId=098f1903694ae, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon May 02 08:12:00 CST 2016, time=2016-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25586, encodeId=6a612558628, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:18:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308211, encodeId=744b1308211cf, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sat May 30 00:12:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314631, encodeId=104813146318c, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat May 30 00:12:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25202, encodeId=958a252020f, content=科技先进啊！, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Thu May 28 16:20:00 CST 2015, time=2015-05-28, status=1, ipAttribution=)]
2016-04-14 xugumin

#review#

30 0
[GetPortalCommentsPageByObjectIdResponse(id=1880677, encodeId=b50618806e750, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 13 03:12:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59867, encodeId=40875986ec9, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:01:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59868, encodeId=a2275986832, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:01:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741264, encodeId=2e591e41264a2, content=<a href='/topic/show?id=329f1540333' target=_blank style='color:#2F92EE;'>#reviews#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15403, encryptionId=329f1540333, topicName=reviews)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9be134907862, createdName=12498ebem30暂无昵称, createdTime=Sat Jul 25 16:12:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995808, encodeId=6f2819958081d, content=<a href='/topic/show?id=a1751540260' target=_blank style='color:#2F92EE;'>#review#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15402, encryptionId=a1751540260, topicName=review)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Thu Apr 14 04:12:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903694, encodeId=098f1903694ae, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon May 02 08:12:00 CST 2016, time=2016-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25586, encodeId=6a612558628, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:18:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308211, encodeId=744b1308211cf, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sat May 30 00:12:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314631, encodeId=104813146318c, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat May 30 00:12:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25202, encodeId=958a252020f, content=科技先进啊！, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Thu May 28 16:20:00 CST 2015, time=2015-05-28, status=1, ipAttribution=)]
2016-05-02 lixiao3326

#新技术#

27 0
[GetPortalCommentsPageByObjectIdResponse(id=1880677, encodeId=b50618806e750, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 13 03:12:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59867, encodeId=40875986ec9, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:01:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59868, encodeId=a2275986832, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:01:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741264, encodeId=2e591e41264a2, content=<a href='/topic/show?id=329f1540333' target=_blank style='color:#2F92EE;'>#reviews#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15403, encryptionId=329f1540333, topicName=reviews)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9be134907862, createdName=12498ebem30暂无昵称, createdTime=Sat Jul 25 16:12:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995808, encodeId=6f2819958081d, content=<a href='/topic/show?id=a1751540260' target=_blank style='color:#2F92EE;'>#review#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15402, encryptionId=a1751540260, topicName=review)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Thu Apr 14 04:12:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903694, encodeId=098f1903694ae, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon May 02 08:12:00 CST 2016, time=2016-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25586, encodeId=6a612558628, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:18:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308211, encodeId=744b1308211cf, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sat May 30 00:12:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314631, encodeId=104813146318c, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat May 30 00:12:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25202, encodeId=958a252020f, content=科技先进啊！, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Thu May 28 16:20:00 CST 2015, time=2015-05-28, status=1, ipAttribution=)]
2015-05-31 huaxipanxing

看看

113 0
[GetPortalCommentsPageByObjectIdResponse(id=1880677, encodeId=b50618806e750, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 13 03:12:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59867, encodeId=40875986ec9, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:01:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59868, encodeId=a2275986832, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:01:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741264, encodeId=2e591e41264a2, content=<a href='/topic/show?id=329f1540333' target=_blank style='color:#2F92EE;'>#reviews#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15403, encryptionId=329f1540333, topicName=reviews)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9be134907862, createdName=12498ebem30暂无昵称, createdTime=Sat Jul 25 16:12:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995808, encodeId=6f2819958081d, content=<a href='/topic/show?id=a1751540260' target=_blank style='color:#2F92EE;'>#review#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15402, encryptionId=a1751540260, topicName=review)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Thu Apr 14 04:12:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903694, encodeId=098f1903694ae, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon May 02 08:12:00 CST 2016, time=2016-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25586, encodeId=6a612558628, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:18:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308211, encodeId=744b1308211cf, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sat May 30 00:12:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314631, encodeId=104813146318c, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat May 30 00:12:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25202, encodeId=958a252020f, content=科技先进啊！, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Thu May 28 16:20:00 CST 2015, time=2015-05-28, status=1, ipAttribution=)]
2015-05-30 flyingeagle77

#抗癌药物#

32 0
[GetPortalCommentsPageByObjectIdResponse(id=1880677, encodeId=b50618806e750, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 13 03:12:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59867, encodeId=40875986ec9, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:01:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59868, encodeId=a2275986832, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:01:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741264, encodeId=2e591e41264a2, content=<a href='/topic/show?id=329f1540333' target=_blank style='color:#2F92EE;'>#reviews#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15403, encryptionId=329f1540333, topicName=reviews)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9be134907862, createdName=12498ebem30暂无昵称, createdTime=Sat Jul 25 16:12:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995808, encodeId=6f2819958081d, content=<a href='/topic/show?id=a1751540260' target=_blank style='color:#2F92EE;'>#review#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15402, encryptionId=a1751540260, topicName=review)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Thu Apr 14 04:12:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903694, encodeId=098f1903694ae, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon May 02 08:12:00 CST 2016, time=2016-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25586, encodeId=6a612558628, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:18:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308211, encodeId=744b1308211cf, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sat May 30 00:12:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314631, encodeId=104813146318c, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat May 30 00:12:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25202, encodeId=958a252020f, content=科技先进啊！, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Thu May 28 16:20:00 CST 2015, time=2015-05-28, status=1, ipAttribution=)]
2015-05-30 sunylz

#抗癌药#

31 0
[GetPortalCommentsPageByObjectIdResponse(id=1880677, encodeId=b50618806e750, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 13 03:12:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59867, encodeId=40875986ec9, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:01:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59868, encodeId=a2275986832, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:01:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741264, encodeId=2e591e41264a2, content=<a href='/topic/show?id=329f1540333' target=_blank style='color:#2F92EE;'>#reviews#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15403, encryptionId=329f1540333, topicName=reviews)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9be134907862, createdName=12498ebem30暂无昵称, createdTime=Sat Jul 25 16:12:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995808, encodeId=6f2819958081d, content=<a href='/topic/show?id=a1751540260' target=_blank style='color:#2F92EE;'>#review#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15402, encryptionId=a1751540260, topicName=review)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Thu Apr 14 04:12:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903694, encodeId=098f1903694ae, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon May 02 08:12:00 CST 2016, time=2016-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25586, encodeId=6a612558628, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:18:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308211, encodeId=744b1308211cf, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sat May 30 00:12:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314631, encodeId=104813146318c, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat May 30 00:12:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25202, encodeId=958a252020f, content=科技先进啊！, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Thu May 28 16:20:00 CST 2015, time=2015-05-28, status=1, ipAttribution=)]
2015-05-28 summer474cn

科技先进啊！

114 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科

Nature Reviews Cancer：抗癌药物直达肿瘤新技术

相关资讯

科室

工具

服务